Zenas BioPharma, Inc.
ZBIO · NASDAQ
Financial statements
Annual and quarterly income, balance-sheet, cash-flow and key-statistics data.
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2022 FY | — | -61.69M | -76.20M | -119.28M | -3.11 |
| 2023 FY | 50.00M | 50.00M | -37.15M | -37.12M | -0.97 |
| 2024 FY | 5.00M | -134.14M | -163.89M | -156.99M | -3.76 |
| 2025 FY | 10.00M | 10.00M | -211.39M | -377.74M | -8.44 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2022 FY | 74.58M | 266.87M | 67.21M | 1.53M | -192.29M |
| 2023 FY | 68.18M | 293.90M | 56.86M | 21.11M | -225.72M |
| 2024 FY | 369.97M | 57.51M | 319.74M | 1.00M | 312.46M |
| 2025 FY | 383.64M | 141.50M | 110.64M | 79.96M | 242.14M |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2022 FY | -65.65M | -2.20M | -67.85M | — | -8.50M |
| 2023 FY | -30.53M | -17.00K | -30.55M | — | -10.35M |
| 2024 FY | -119.67M | -131.00K | -119.81M | — | 262.89M |
| 2025 FY | -172.33M | -18.00K | -172.35M | — | -209.19M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2022 FY | 688.56M | 622.88M | — | — | — |
| 2023 FY | 688.56M | 652.81M | — | — | — |
| 2024 FY | 342.22M | 23.48M | — | — | — |
| 2025 FY | 1.62B | 1.59B | — | — | — |
| 2026-12-31 | — | — | — | — | — |
| 2027-12-31 | — | — | — | — | — |
| 2028-12-31 | — | — | — | — | — |
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 Q2 | — | -43.03M | -55.16M | -52.22M | -1.25 |
| 2025 Q3 | — | -5.00M | -52.58M | -51.50M | -1.22 |
| 2025 Q4 | — | -55.72M | -237.98M | -240.44M | -5.17 |
| 2026 Q1 | — | -6.00K | -77.35M | -80.99M | -1.46 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2025 Q2 | 293.09M | 53.46M | 44.01M | 1.01M | 239.63M |
| 2025 Q3 | 322.02M | 125.59M | 115.57M | 798.00K | 196.43M |
| 2025 Q4 | 383.64M | 141.50M | 110.64M | 79.96M | 242.14M |
| 2026 Q1 | 747.68M | 411.85M | 500.22M | 351.73M | 335.83M |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2025 Q2 | -41.74M | — | -41.74M | — | -152.55M |
| 2025 Q3 | -41.13M | — | -41.13M | — | 71.56M |
| 2025 Q4 | -52.41M | — | -52.41M | — | -4.92M |
| 2026 Q1 | -75.20M | -2.00K | -75.20M | — | 389.58M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2025 Q2 | 405.68M | 362.68M | — | — | — |
| 2025 Q3 | 935.94M | 821.17M | — | — | — |
| 2025 Q4 | 1.69B | 1.66B | — | — | — |
| 2026 Q1 | 1.09B | 938.97M | — | — | — |
| 2026-06-30 | — | — | — | — | — |
| 2026-09-30 | — | — | — | — | — |
| 2026-12-31 | — | — | — | — | — |